Your browser doesn't support javascript.
loading
A unique phenotype of acquired Glanzmann thrombasthenia due to non-function-blocking anti-αIIbß3 autoantibodies.
Akuta, K; Kashiwagi, H; Yujiri, T; Nishiura, N; Morikawa, Y; Kato, H; Honda, S; Kanakura, Y; Tomiyama, Y.
Afiliação
  • Akuta K; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Kashiwagi H; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Yujiri T; Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Japan.
  • Nishiura N; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Morikawa Y; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Kato H; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Honda S; Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center, Suita, Japan.
  • Kanakura Y; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Tomiyama Y; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
J Thromb Haemost ; 17(1): 206-219, 2019 01.
Article em En | MEDLINE | ID: mdl-30388316
ABSTRACT
Essentials Acquired Glanzmann thrombasthenia (aGT) is generally caused by function-blocking antibodies (Abs). We demonstrated a unique aGT case due to marked reduction of αIIbß3 with anti-αIIbß3 Abs. The anti-αIIbß3 Abs of the patient did not inhibit platelet function but reduced surface αIIbß3. Internalization of αIIbß3 induced by the Abs binding may be responsible for the phenotype.

SUMMARY:

Background Acquired Glanzmann thrombasthenia (aGT) is a bleeding disorder generally caused by function-blocking anti-αIIbß3 autoantibodies. Aim We characterize an unusual case of aGT caused by marked reduction of surface αIIbß3 with non-function-blocking anti-αIIbß3 antibodies (Abs). Methods A 72-year-old male suffering from immune thrombocytopenia since his 50s showed exacerbation of bleeding symptom despite mild thrombocytopenia. Platelet aggregation was absent with all agonists but ristocetin. Analysis of αIIbß3 expression and genetic analysis were performed. We also analyzed effects of anti-αIIbß3 Abs of the patient on platelet function and αIIbß3 expression. Results Surface αIIbß3 expression was markedly reduced to around 5% of normal, whereas his platelets contained αIIbß3 to the amount of 40-50% of normal. A substantial amount of fibrinogen was also detected in his platelets. There were no abnormalities in ITGA2B and ITGB3 cDNA. These results indicated that reduced surface αIIbß3 expression caused a GT phenotype, and active internalization of αIIbß3 was suggested. Anti-αIIbß3 IgG Abs were detected in platelet eluate and plasma. These Abs did not inhibit PAC-1 binding, indicating that the Abs were non-function-blocking. Surface αIIbß3 expression of a megakaryocytic cell line and cultured megakaryocytes tended to be impaired by incubation with the patient's Abs. After 2 years of aGT diagnosis, his bleeding symptom improved and surface αIIbß3 expression was recovered to 20% of normal with reduction of anti-αIIbß3 Abs. Conclusion We demonstrated a unique aGT phenotype due to marked reduction of surface αIIbß3. Internalization induced by anti-αIIbß3 Abs may be responsible in part for the phenotype.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Autoanticorpos / Plaquetas / Trombastenia / Complexo Glicoproteico GPIIb-IIIa de Plaquetas / Integrina alfa2 / Integrina beta3 Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Autoanticorpos / Plaquetas / Trombastenia / Complexo Glicoproteico GPIIb-IIIa de Plaquetas / Integrina alfa2 / Integrina beta3 Idioma: En Ano de publicação: 2019 Tipo de documento: Article